2026 AACR Renal Cell Carcinoma Highlights

The Lank Center for Genitourinary Oncology at Dana-Farber Cancer Institute presents a succinct summary of all the renal cell carcinoma clinical updates you need to know from AACR 2026. Highlights in this video include: • RCC highlights emphasized biology-driven innovation, including PLN-101095 for TGF-β/integrin-mediated immune re-sensitization, ENPP3 as a potential ADC target, and NEO-811 as a first-in-class ARNT degrader targeting the hypoxia axis in ccRCC. • The SPARC-1 study showed that neoadjuvant IL-1 plus PD-1 inhibition in localized ccRCC is feasible, safe, and biologically active, with correlative evidence of myeloid reprogramming and T-cell reinvigoration before surgery.